Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031785 · ClinicalTrials.gov registry record · Phase 3
Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer
A Phase 3 study of Lung Cancer and Cachexia, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT00031785 is a Phase 3 study of Lung Cancer and Cachexia that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 25 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00031785, a Phase 3 study of Lung Cancer and Cachexia, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Megestrol helps improve appetite. It is not yet known if megestrol is effective in limiting weight loss in patients who are undergoing radiation therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of megestrol in limiting weight loss in patients who are undergoing radiation therapy for lung cancer.
Conditions Studied
Interventions
- RADIATION radiation therapy
- DRUG megestrol acetate
Study Locations (1)
North Carolina
- Comprehensive Cancer Center at Wake Forest University - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2000-09-01 |
| Est. Completion | 2002-09-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00031785
The ClinicalTrials.gov registry entry for NCT00031785 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which radiation therapy is the first listed.
NCT00031785 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00031785 about?
NCT00031785 is a clinical study titled "Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer". RATIONALE: Megestrol helps improve appetite. It is not yet known if megestrol is effective in limiting weight loss in patients who are undergoing radiation therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of megestrol in limiting weight loss in patients who are undergoing...
What is the current status of trial NCT00031785?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 25 participants. The study started on 2000-09-01. Estimated completion is 2002-09-11.
What conditions does trial NCT00031785 study?
This clinical trial studies the following conditions: Lung Cancer, Cachexia, Anorexia.
What interventions are being tested in trial NCT00031785?
The interventions under investigation include: radiation therapy (RADIATION), megestrol acetate (DRUG).
Who is sponsoring clinical trial NCT00031785?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00031785 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
ACTIVE NOT RECRUITING · Phase 3
-
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
COMPLETED · Phase 3
-
Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.